FindTrial
Sign In

NovoTTF-200A Device

DEVICE3 trials

Sponsors

Northwestern University, Sidney Kimmel Cancer Center at Thomas Jefferson University, Vanderbilt-Ingram Cancer Center

Conditions

Anaplastic (Malignant) MeningiomaAtypical MeningiomaExtensive Stage Small Cell Lung CarcinomaGlioblastomaGrade II MeningiomaGrade III MeningiomaRecurrent MeningiomaSupratentorial Meningioma

Early Phase 1

Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma
CompletedNCT03477110
Sidney Kimmel Cancer Center at Thomas Jefferson UniversityGlioblastoma
Start: 2018-05-04End: 2024-01-26Updated: 2025-05-15

Phase 2

Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
RecruitingNCT02847559
Northwestern UniversityAnaplastic (Malignant) Meningioma, Atypical Meningioma, Grade III Meningioma +3
Start: 2016-08-01End: 2026-12-31Target: 27Updated: 2025-06-27

Unknown Phase

Tumor-Treating Fields Therapy in Preventing Brain Tumors in Participants With Extensive-Stage Small Cell Lung Cancer
TerminatedNCT03607682
Vanderbilt-Ingram Cancer CenterExtensive Stage Small Cell Lung Carcinoma
Start: 2018-09-05End: 2020-07-13Updated: 2020-08-04

Related Papers

Case report: durable response of gliomatosis cerebri with concurrent tumor-treating fields (TTFields) and chemoradiotherapy treatment.
2023-12-011 citations
Molecular markers impacting survival in patients receiving concurrent chemoradiation and Tumor-Treating Fields (TTF) in patients with newly diagnosed glioblastoma: secondary analysis of SPARE trial (P13-13.003)
Neurology2023-04-25
Concurrent chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for patients with newly diagnosed glioblastoma: patterns of progression in a single institution pilot study.
2022-11-1013 citations
RADT-19. CHEMORADIATION (CRT) TREATMENT WITH OR WITHOUT CONCURRENT TUMOR-TREATING FIELDS (TTFIELDS) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Neuro-Oncology2022-11-01
INNV-09. IMPACT OF MOLECULAR MARKERS ON TREATMENT OUTCOME OF GLIOBLASTOMA PATIENTS TREATED WITH CONCURRENT TUMOR-TREATING FIELDS (TTF) AND CHEMORADIATION: SECONDARY ANALYSIS OF SPARE TRIAL
Neuro-Oncology2022-11-01
Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma
Frontiers in Oncology2022-04-2929 citations
CTNI-19. CONCURRENT CHEMORADIATION AND TUMOR TREATING FIELDS (TTFields, 200 kHz) FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MAY INCREASE THE RATE OF DISTANT RECURRENCE
Neuro-Oncology2021-11-02
RADT-22. CONCURRENT TTFIELDS (200 KHZ) WITH CHEMORADIATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MAY INCREASE THE RATE OF PSEUDOPROGRESSION: ANALYSIS OF A PILOT CLINICAL TRIAL
Neuro-Oncology2021-11-02
Concurrent TTFields (200 kHz) With Chemoradiation for Patients With Newly Diagnosed Glioblastoma May Increase the Rate of Pseudoprogression: Analysis of a Pilot Clinical Trial.
2021-11-01
Concurrent Chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for Patients With Newly Diagnosed Glioblastoma May Increase the Rate of Distant Recurrence.
2021-11-01
Scalp-sparing radiation with concurrent temozolomide and tumor treating fields (SPARE) for patients with newly diagnosed glioblastoma.
Journal of Clinical Oncology2021-05-204 citations
NCOG-52. TUMOR TREATING FIELDS IN MENINGIOMA
Neuro-Oncology2020-11-011 citations
CTNI-59. FIRST SAFETY ANALYSIS OF ANAPLASTIC MENINGIOMA PATIENTS TREATED WITH TUMOR TREATING FIELDS (TTFIELDS)
Neuro-Oncology2020-11-01
CTNI-21. SCALP SPARING RADIATION WITH CONCURRENT TEMOZOLOMIDE AND TUMOR TREATMENT FIELDS (SPARE) FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Neuro-Oncology2020-11-01
Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma.
2020-03-2321 citations
ATIM-02. TUMOR TREATING FIELDS IN COMBINATION WITH BEVACIZUMAB IN RECURRENT OR PROGRESSIVE MENINGIOMA IN A PHASE 2 STUDY
Neuro-Oncology2018-11-011 citations
Abstract CT081: Tumor treating fields in combination with Bevacizumab in recurrent or progressive meningioma in a phase II study
Cancer Research2018-07-01
ACTR-19. A PHASE 2 STUDY OF TUMOR TREATING FIELDS AND BEVACIZUMAB IN RECURRENT OR PROGRESSIVE MENINGIOMA
Neuro-Oncology2017-11-01